GLP 1 Companion Nutrition Market Size, Share, Scope, Forecast Report 2026 to 2035

What is GLP 1 Companion Nutrition Market Size?

GLP 1 Companion Nutrition Market is expected to grow at a 13.6% CAGR during the forecast period for 2026 to 2035.

GLP 1 Companion Nutrition Market Size, Share & Trends Analysis Distribution By Product Category (Protein Powders & Drink Mixes, Ready-to-Drink (RTD) Protein Shakes, Meal Replacement & Complete Nutrition Shakes, High-Protein Nutrition Bars & Snack Bars, Muscle Preservation & Lean Mass Supplements, Vitamins, Minerals & Multivitamin Formulations, Electrolyte & Hydration Supplements, Digestive Health, Fiber & Probiotic Supplements, Collagen & Beauty-from-Within Products, Prebiotic Fiber & Natural GLP-1 Support Supplements, Broths, Bone Broths & Liquid Nutrition), By Protein Source (Dairy-Based (Whey Protein Concentrate, Whey Protein Isolate, Whey Protein Hydrolysate, Micellar Casein, Milk Protein Concentrate & Isolate), Plant-Based (Pea Protein Isolate, Soy Protein Isolate, Rice & Brown Rice Protein, Hemp, Chia & Algal Protein, Fava, Mung Bean & Pulse Proteins), Collagen Peptides (Bovine, Marine, Chicken), Egg White Protein, Blended Protein Systems (Dairy + Plant), by Functional Ingredient, by Formulation / Delivery Format, by Consumer Use Stage, by Price Tier, by Distribution Channel,   by End Users and Segment Forecasts, 2026 to 2035

GLP-1 Companion Nutrition is an emerging category of dietary products created to support people using GLP-1 receptor agonist drugs—like semaglutide and tirzepatide—for obesity, weight management, or type 2 diabetes. These medications work by reducing hunger, slowing stomach emptying, and altering food preferences, which can lead to lower calorie intake and, in some cases, unintended side effects such as nausea, constipation, and loss of lean muscle mass.

Companion nutrition products are specifically formulated to address these challenges. They include high-protein shakes and bars to help preserve muscle during rapid weight loss, small-portion meals that are nutrient-dense yet easy to digest, fiber-rich options to support gut health, and hydration solutions with electrolytes to counteract fluid imbalances. The goal is not to replace the medication but to complement it—ensuring that individuals receive adequate protein, vitamins, and minerals while managing side effects and maintaining energy levels.

The market is also benefiting from increasing awareness around obesity and metabolic disorders, along with a growing focus on preventive healthcare and lifestyle management. Consumers are becoming more proactive about combining medical treatments with proper nutrition to achieve better outcomes. This has encouraged both established nutrition brands and new entrants to invest in research and product innovation, particularly in high-protein formulations, clean-label ingredients, and functional nutrition tailored to metabolic health. In addition, the rise of direct-to-consumer channels, digital health platforms, and personalized nutrition plans is making these products more accessible. Healthcare providers, including dietitians and weight management specialists, are also playing a key role in recommending companion nutrition as part of a structured treatment approach. 

However, the market faces challenges, including the need for stronger clinical validation, varying patient responses, and the importance of clear guidance on proper use alongside GLP-1 therapies. Despite these hurdles, the outlook for the GLP-1 companion nutrition market remains highly positive. Continuous innovation, increasing collaboration between pharmaceutical and nutrition companies, and a growing emphasis on integrated care are expected to drive long-term growth. Overall, this market is becoming an essential extension of GLP-1 therapy, helping patients achieve more balanced, sustainable, and effective health outcomes.

Competitive Landscape

Which are the Leading Players in the GLP-1 Companion Nutrition Market?

• Youtheory
• Shaklee Corporation
• Ora Organic
• Supergut
• Lemme
• Ritual
• Thorne HealthTech
• Designs for Health
• Lumen
• Needed
• Glanbia plc
• Abbott Laboratories
• Nestlé Health Science
• Danone S.A.
• BellRing Brands
• The Simply Good Foods Company
• Herbalife
• GNC Holdings
• Iovate Health Sciences
• Huel
• Kodiak Cakes
• Reckitt
• FrieslandCampina Ingredients
• Arla Foods Ingredients
• Valio Ltd.
• Fonterra
• Glanbia Nutritionals
• Kerry Group
• dsm-firmenich
• Archer Daniels Midland
• Roquette
• Ingredion Incorporated
• Tate & Lyle
• Beneo
• Ajinomoto
• CJ CheilJedang
• Evonik Industries
• Cargill
• Nutricia
• Perrigo
• Prolacta Bioscience
• Hormel Health Labs
• Seed Health
• Pendulum Therapeutics
• Kenvue
• Olipop
• PepsiCo
• LMNT
• Unilever
• DripDrop
• Ultima Replenisher

Market Dynamics

Driver

Growing Need for Nutritional Support Alongside GLP-1 Therapies

The key drivers of the GLP-1 companion nutrition market is the increasing use of GLP-1–based treatments for weight management and metabolic health. While these therapies are highly effective, they often lead to reduced appetite, lower calorie intake, and potential nutrient gaps. As a result, there is a growing need for targeted nutrition to help individuals maintain muscle mass, energy levels, and overall health during treatment. Companion nutrition products are designed to address these specific needs simply and conveniently. Options such as protein powders, ready-to-drink shakes, meal replacements, and electrolyte supplements make it easier for patients to meet their daily nutritional requirements without relying on large meals. This is particularly valuable for individuals undergoing long-term therapy or managing chronic conditions. As awareness grows among both patients and healthcare providers, companion nutrition is increasingly becoming an essential part of the overall treatment journey rather than an optional add-on.

Restrain/Challenge

Lack of Standardization and Individual Variability in Nutritional Needs

Despite strong growth potential, the market faces challenges related to variability in patient needs and the lack of standardized nutritional guidelines. Individuals using GLP-1 therapies may experience different levels of appetite suppression, digestive changes, and metabolic responses, making it difficult to design a one-size-fits-all nutrition solution. Additionally, while there is growing interest in companion nutrition, clinical validation for many products is still evolving. Consumers may also feel overwhelmed by the wide range of available options, from protein supplements and vitamins to probiotics and functional foods, without clear guidance on what works best for their specific stage of treatment. This creates a need for better education, personalization, and stronger alignment between healthcare providers and nutrition brands.

Ready-to-Drink (RTD) Protein Shakes Subsegment is Driving the GLP-1 Companion Nutrition Market

The ready-to-drink (RTD) protein shakes subsegment is emerging as one of the strongest drivers in the GLP-1 companion nutrition market, driven by unmatched convenience and ease of consumption. Individuals undergoing GLP-1 therapy often experience reduced appetite, making it difficult to prepare or consume full meals. RTD shakes address this challenge by offering a quick, nutritionally balanced option that requires no preparation and can be consumed anytime, anywhere. These products are especially effective in helping users maintain adequate protein intake, which is critical for preserving muscle mass during weight loss. In addition, many RTD shakes are now being formulated with added vitamins, minerals, and functional ingredients to support overall health, energy levels, and metabolic balance. Their availability across retail stores, pharmacies, and online platforms further boosts accessibility. As a result, the combination of convenience, targeted nutrition, and growing consumer preference for on-the-go solutions makes RTD protein shakes a key growth driver in the market.

Prebiotic Fiber & Digestive Health Supplements Subsegment is Driving the GLP-1 Companion Nutrition Market

The prebiotic fiber and digestive health supplements subsegment is also playing a crucial role in driving the GLP-1 companion nutrition market. GLP-1 therapies can sometimes cause digestive changes, such as slowed gastric emptying, bloating, or discomfort. This has increased the demand for products that support gut health and improve digestion during treatment. Prebiotic fibers, probiotics, and digestive enzymes help maintain a healthy gut environment, improve nutrient absorption, and enhance overall comfort for users. These supplements are particularly valuable for ensuring that reduced food intake does not negatively impact digestive function or long-term health. In addition, growing awareness around the importance of gut health and its connection to metabolism and immunity is further accelerating demand. With more brands focusing on clean-label, scientifically backed formulations, this subsegment is gaining strong consumer trust. Its ability to directly address a common pain point of GLP-1 users makes it an important contributor to market growth and product innovation.

Why North America Led the GLP-1 Companion Nutrition Market?

North America leads the GLP-1 companion nutrition market due to a combination of strong healthcare infrastructure, high adoption of GLP-1 therapies, and a well-developed nutrition industry. The United States, in particular, has seen rapid growth in the use of these therapies, creating a parallel demand for supportive nutrition solutions. The region benefits from high consumer awareness, a strong culture of health and wellness, and easy access to a wide range of products through both retail and digital channels. Additionally, the presence of leading nutrition brands, advanced research capabilities, and active involvement from healthcare providers contributes to faster innovation and adoption. The rise of telehealth platforms and personalized treatment programs has further strengthened the market, as many providers now offer bundled solutions that include both medication and nutrition support. Overall, North America’s leadership is driven by the right mix of consumer demand, innovation, accessibility, and integrated healthcare approaches.

Key Developments

• In March 2025, Nestlé Health Science expanded its medical nutrition portfolio with targeted high-protein and metabolic health solutions aimed at supporting individuals on weight management therapies, strengthening its position in the GLP-1 companion nutrition space.

• In February 2025, Abbott Laboratories introduced advanced nutrition formulations under its adult nutrition segment, focusing on muscle preservation and balanced nutrition for patients undergoing metabolic and weight-loss treatments.

GLP-1 Companion Nutrition Market Report Scope: